Oncology (all articles)
Guideline | Fecal immunochemical testing in patients with signs or symptoms of suspected colorectal cancer.
31 Aug, 2022 | 11:52h | UTCCommentary: Guidelines update: use of FIT in colorectal cancer referrals – PULSE
Cohort Study | 5-year follow-up results suggest it is safe to de-escalate radiotherapy after primary chemotherapy in cT1–2N1 breast cancer.
31 Aug, 2022 | 11:45h | UTCDe-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 2010–03): 5-year follow-up results of a Dutch, prospective, registry study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
At 5-year follow up in RAPCHEM, BOOG 2010–03 study of locoregional RT de-escalation in cT1-2N1 breast cancer, locoregional recurrence rates were 2.3%, 1.0% and 1.4% in low, intermediate and high risk groups, and therefore this approach was considered safe: https://t.co/4NkUwr4kxV
— NatureRevClinOncol (@NatRevClinOncol) August 15, 2022
RCT | Optical coherence tomography vs. punch biopsy for diagnosis of basal cell carcinoma.
31 Aug, 2022 | 11:31h | UTCOptical coherence tomography versus punch biopsy for diagnosis of basal cell carcinoma: a multicentre, randomised, non-inferiority trial – The Lancet Oncology (link to abstract – $ for full-text)
Meta analysis of randomized trials | Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer.
30 Aug, 2022 | 12:07h | UTCAssociation of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials – JAMA Oncology (free for a limited period)
Commentary on Twitter
In this meta-analysis of >11,000 patients with advanced gastroesophageal cancer, tissue PD-L1 expression — more than other variables besides microsatellite-high — identified varying degrees of benefit from immunotherapy-containing therapy. https://t.co/oUEDIEqLFj
— JAMA Oncology (@JAMAOnc) August 25, 2022
RCT | Colorectal Endoscopic Stenting Trial (CReST) for obstructing left-sided colorectal cancer.
30 Aug, 2022 | 11:58h | UTC
Cohort Study | Outcomes of patients with sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm under active surveillance.
30 Aug, 2022 | 11:57h | UTC
#ESCCongress | 2022 ESC Guidelines on cardio-oncology.
29 Aug, 2022 | 12:17h | UTCNews Release: Advice to prevent heart problems caused by cancer therapy published today – European Society of Cardiology
Related guidelines:
Brazilian Cardio-oncology Guideline – 2020 – Arquivos Brasileiros de Cardiologia
RCT | Cemiplimab plus chemotherapy vs. chemotherapy alone in non-small cell lung cancer.
29 Aug, 2022 | 12:08h | UTC
Commentary on Twitter
Results from EMPOWER-Lung 3 demonstrate increased overall survival with #cemiplimab plus platinum-doublet #chemotherapy compared with cemiplimab as first-line treatment in patients with advanced non-small cell #LungCancer, irrespective of #PD-L1 expressionhttps://t.co/ojCDeivKzC
— Nature Medicine (@NatureMedicine) August 25, 2022
RCT | Sacituzumab Govitecan in hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer.
29 Aug, 2022 | 12:05h | UTC
A simple cervicovaginal epigenetic test for screening and rapid triage of women with suspected endometrial cancer: validation in several cohort and case/control sets.
29 Aug, 2022 | 11:58h | UTC
Commentary on Twitter
Pleased to share our work out today in J Clin Oncol "A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer …" #FORECEE #CCBIO #H2020 @eveappeal @Gynkreft @medofak_uib @haukeland_no
#screening https://t.co/Av53WSWqoQ pic.twitter.com/dL4j7nW7vt— Line Bjørge (@DrLB) August 24, 2022
Under a https://creativecommons.org/licenses/by/4.0/ license
RCT | HPV self-sampling among long-term non-attenders to cervical cancer screening.
26 Aug, 2022 | 13:27h | UTC
Commentary on Twitter
Pragmatic randomised controlled trial of 3 different HPV screening approaches suggests that opt-in and particularlly send-to-all self-sampling increased participation among long-term, higher-risk non-attenders: https://t.co/hBouqoBMnU #GynCSM #hsronc
— NatureRevClinOncol (@NatRevClinOncol) August 25, 2022
Clinical practice guidelines for intrahepatic cholangiocarcinoma.
26 Aug, 2022 | 13:20h | UTC
Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus.
26 Aug, 2022 | 13:19h | UTC
Endocervical sampling in women with suspected cervical neoplasia: a systematic review and meta-analysis of diagnostic test accuracy studies.
26 Aug, 2022 | 13:18h | UTC
Systematic Review | Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
26 Aug, 2022 | 13:11h | UTC
RCT | Talimogene Laherparepvec plus Pembrolizumab not better than placebo-Pembrolizumab in patients with advanced melanoma.
26 Aug, 2022 | 13:09h | UTC
Triple negative breast cancer: pitfalls and progress.
26 Aug, 2022 | 13:02h | UTCTriple negative breast cancer: Pitfalls and progress – npj Breast Cancer
RCT | In patients with low-risk nasopharyngeal carcinoma, radiotherapy alone was noninferior to radiotherapy plus concurrent chemoradiotherapy on survival without disease relapse at 3 years.
25 Aug, 2022 | 12:13h | UTCEffect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial – JAMA (free for a limited period)
Video Editor’s Note: Radiotherapy With vs Without Chemoradiotherapy in Low-risk Nasopharyngeal Carcinoma – JAMA
Cohort Study | Association between changes in alcohol consumption and cancer risk.
25 Aug, 2022 | 12:03h | UTCAssociation Between Changes in Alcohol Consumption and Cancer Risk – JAMA Network Open
Invited Commentary: Reducing Alcohol Use for Cancer Prevention – JAMA Network Open
Network M-A | Efficacy of various adjuvant chemotherapy methods in preventing liver metastasis from potentially curative colorectal cancer.
25 Aug, 2022 | 12:01h | UTC
Phase 2 RCT | Adjuvant intravesical chemohyperthermia not better than passive chemotherapy in patients with intermediate-risk non–muscle-invasive bladder cancer.
25 Aug, 2022 | 12:00h | UTC
Commentary on Twitter
No benefit of adjuvant intravesical hyperthermic chemo (CHT) for intermediate-risk non–muscle-invasive bladder cancer
🔸DFS @ 24 mo was 61% vs 60%
🔸Patients treated with CHT were less likely to complete their treatment @EUplatinum @OncoAlert @Uroweb https://t.co/q8lB2MxBFf pic.twitter.com/E8Ay5hirBb— Yüksel Ürün (@DrYukselUrun) August 22, 2022
Under a Creative Commons license
Observational study suggests frequent aspirin use may reduce the risk of ovarian cancer.
25 Aug, 2022 | 11:49h | UTCModification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentaries:
Frequent Aspirin Use Tied to Lower Ovarian Cancer Risk – HealthDay
Commentary on Twitter
💊 Frequent aspirin use ⬇️ #OvarianCancer risk among women with other risk factors for ovarian cancer
Read more in #JCO: https://t.co/QV4bK0lB5M #prevention #gyncsm #ovca @LaurenMHurwitz @b_trabert pic.twitter.com/xvU1yb60mi
— Journal of Clinical Oncology (@JCO_ASCO) August 18, 2022
RCT | Nivolumab vs. nivolumab plus docetaxel for previously treated advanced or recurrent immune checkpoint inhibitor-naïve non-small-cell lung cancer.
25 Aug, 2022 | 11:48h | UTC
M-A of randomized trials | Risk of cutaneous adverse events in cancer patients treated with phosphatidylinositol-3-kinase inhibitors.
24 Aug, 2022 | 14:12h | UTC
M-A | Androgen receptor signaling inhibitors in addition to Docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.
24 Aug, 2022 | 13:58h | UTC